OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 214 Thousand SEK | -97.96% |
| 2022 | 10.5 Million SEK | -6.49% |
| 2021 | 11.23 Million SEK | -19.74% |
| 2020 | 13.99 Million SEK | 325.99% |
| 2019 | 3.28 Million SEK | -53.51% |
| 2018 | 7.06 Million SEK | -14.38% |
| 2017 | 8.25 Million SEK | 119.29% |
| 2016 | 3.76 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 86 Thousand SEK | -59.81% |
| 2024 Q2 | 1.31 Million SEK | -100.0% |
| 2023 Q4 | 214 Thousand SEK | -97.55% |
| 2023 Q2 | 8.94 Million SEK | -8.29% |
| 2023 FY | 214 Thousand SEK | -97.96% |
| 2023 Q1 | 9.75 Million SEK | -7.2% |
| 2023 Q3 | 8.72 Million SEK | -2.46% |
| 2022 Q4 | 10.5 Million SEK | -7.04% |
| 2022 Q2 | 12.09 Million SEK | -6.1% |
| 2022 FY | 10.5 Million SEK | -6.49% |
| 2022 Q1 | 12.87 Million SEK | 14.62% |
| 2022 Q3 | 11.3 Million SEK | -6.53% |
| 2021 Q3 | 11.9 Million SEK | -7.58% |
| 2021 FY | 11.23 Million SEK | -19.74% |
| 2021 Q4 | 11.23 Million SEK | -5.62% |
| 2021 Q2 | 12.88 Million SEK | -3.18% |
| 2021 Q1 | 13.3 Million SEK | -4.96% |
| 2020 Q2 | 10.39 Million SEK | 250.66% |
| 2020 FY | 13.99 Million SEK | 325.99% |
| 2020 Q3 | 14.53 Million SEK | 39.91% |
| 2020 Q1 | 2.96 Million SEK | -9.83% |
| 2020 Q4 | 13.99 Million SEK | -3.71% |
| 2019 Q3 | 3.52 Million SEK | -7.29% |
| 2019 Q1 | 6.71 Million SEK | -5.07% |
| 2019 FY | 3.28 Million SEK | -53.51% |
| 2019 Q4 | 3.28 Million SEK | -6.73% |
| 2019 Q2 | 3.8 Million SEK | -43.37% |
| 2018 FY | 7.06 Million SEK | -14.38% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | 7.06 Million SEK | 0.0% |
| 2017 FY | 8.25 Million SEK | 119.29% |
| 2016 FY | 3.76 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.985% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.985% |
| Arcoma AB | 1.92 Million SEK | 88.895% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 99.494% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.988% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 99.629% |
| CellaVision AB (publ) | 28.66 Million SEK | 99.253% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | 4.036% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | 87.792% |
| Duearity AB (publ) | 2.94 Million SEK | 92.721% |
| Dignitana AB (publ) | 6.07 Million SEK | 96.479% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 90.696% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.995% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 96.631% |
| Iconovo AB (publ) | 4.9 Million SEK | 95.639% |
| Integrum AB (publ) | 4.84 Million SEK | 95.583% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -3.871% |
| Mentice AB (publ) | 2.14 Million SEK | 90.019% |
| Paxman AB (publ) | 2.53 Million SEK | 91.548% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 92.876% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 94.879% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 98.886% |
| Sedana Medical AB (publ) | 1.01 Million SEK | 78.854% |
| Senzime AB (publ) | 8.57 Million SEK | 97.505% |
| SpectraCure AB (publ) | 4.39 Million SEK | 95.133% |
| Stille AB | 38.06 Million SEK | 99.438% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.989% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 98.989% |